Navigation Links
Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
Date:2/22/2012

SAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Citi 2012 Global Healthcare Conference in New York on Wednesday, February 29, 2012 at 11:00 a.m. ET / 8:00 a.m. PT. Kurt Gustafson, Chief Financial Officer, Halozyme Therapeutics, will provide a corporate overview.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
2. Halozyme Announces Proposed Public Offering of Common Stock
3. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
4. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
5. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
6. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
7. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
8. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
9. Halozyme Therapeutics to Present at Upcoming Financial Conferences
10. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
11. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)...  Soligenix, Inc. (Nasdaq: SNGX ) ... focused on developing and commercializing products to treat ... need, announced today that its proprietary formulation of ... for the treatment of psoriasis. The issued patent, ... skin conditions, complements the method of treatment claims ...
(Date:2/21/2017)... NEW YORK , Feb. 21, 2017 /PRNewswire/ ... the full report: http://www.reportlinker.com/p04711309-summary/view-report.html ... current as well as future prospects of the ... companies and intermediaries engaged in the manufacture and ... as well as new entrants planning to enter ...
(Date:2/21/2017)... , Feb. 21, 2017 The global infusion ... of 6.0% from 2016 to 2021, to reach USD ... 2016. Increasing prevalence of chronic diseases along with increasing ... reduce hospital expenditure, steady increase in surgical procedural volumes, ... are some of the key factors driving the growth ...
Breaking Medicine Technology:
(Date:2/22/2017)... CT (PRWEB) , ... February 22, 2017 , ... The ... and the 2017 Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A ... webinar is part of the Interactive Webinar Series. , If you want to find ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS is a nonprofit mental ... Established in 1977, our organization was at the forefront in working with veterans ... life were evident and served as the catalyst for the establishing the agency. ...
(Date:2/22/2017)... Wis (PRWEB) , ... February 22, 2017 , ... ... a category by itself - the Vector™ Series Multi-Cook Oven offers up to ... oven chamber, featuring exclusive Structured Air Technology™ for unmatched evenness in cooking. Alto-Shaam ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & Morton ... Durant, Oklahoma, on Feb. 21. , The celebration began with a ribbon cutting ... employees, the construction team and tribal leadership. , Choctaw Nation Durant Regional ...
(Date:2/21/2017)... , ... February 21, 2017 , ... As recently as ... according to the American Society of Plastic Surgeons. Some patients want to make a ... of their nose and improve their breathing ability. The team at usrhinoplasty.org ...
Breaking Medicine News(10 mins):